Sai Phanindra Venkatapurapu, Lindsay E. Clegg, Andrzej Nowojewski, Holly Kimko, Damilola Olabode, Aarti Sawant-Basak, Karthick Vishwanathan
Digital twins can revolutionize drug development and personalized care by accelerating timelines, reducing costs and failure rates, and potentially improving the safety and efficacy of new therapies. In this review, we explore different applications of digital twins across the pharmaceutical value chain, from target discovery and preclinical research to clinical trials, regulatory review, manufacturing and post-market clinical practice. Key challenges, however, remain in data integration, model reliability, regulatory acceptance and data privacy. Overcoming these barriers will require innovation, transparency and collaborative efforts across the healthcare ecosystem to fully realize digital twin potential for patients, healthcare providers and the pharmaceutical industry.